Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington’s disease mouse model

The present study describes evaluation of epigenetic regulation by a small molecule as the therapeutic potential for treatment of Huntington’s disease (HD). We identified 5-allyloxy-2-(pyrrolidin-1-yl)quinoline (APQ) as a novel SETDB1/ESET inhibitor using a combined in silico and in vitro cell based...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Enzyme Inhib Med Chem
Autori principali: Hwang, Yu Jin, Hyeon, Seung Jae, Kim, Younghee, Lim, Sungsu, Lee, Min Young, Kim, Jieun, Londhe, Ashwini M., Gotina, Lizaveta, Kim, Yunha, Pae, Ae Nim, Cho, Yong Seo, Seong, Jihye, Seo, Hyemyung, Kim, Yun Kyung, Choo, Hyunah, Ryu, Hoon, Min, Sun-Joon
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2021
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8008885/
https://ncbi.nlm.nih.gov/pubmed/33771089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14756366.2021.1900160
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi